Oct 30 (Reuters) - Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Savio D'Souza)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | -6.30% | -39.36% | -66.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.80% | 47.74M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- RVPH Stock
- News Reviva Pharmaceuticals Holdings, Inc.
- Reviva Pharma's schizophrenia drug succeeds in late-stage study